Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Autor: Langslet, Gisle¹ (AUTHOR), Nyström, Thomas² (AUTHOR), Vistisen, Dorte^3,4 (AUTHOR), Carstensen, Bendix³ (AUTHOR), Grip, Emilie Toresson^5,6 (AUTHOR), Casajust, Paula⁷ (AUTHOR), Tskhvarashvili, Giorgi⁸ (AUTHOR), Hoti, Fabian⁹ (AUTHOR), Klement, Riho¹⁰ (AUTHOR), Karlsdotter, Kristina¹¹ (AUTHOR), Tuovinen, Mikko¹² (AUTHOR), Ofstad, Anne Pernille^13,14 (AUTHOR), Lajer, Maria¹⁵ (AUTHOR), Shay, Christina¹⁶ (AUTHOR) christina.shay@boehringer-ingelheim.com, Koeneman, Lisette¹⁷ (AUTHOR), Farsani, Soulmaz Fazeli¹⁸ (AUTHOR), Niskanen, Leo^19,20 (AUTHOR), Halvorsen, Sigrun^21,22 (AUTHOR), Infante, Marco (AUTHOR) marco.infante@unicamillus.org

Publikováno v: Journal of Diabetes Research. 10/12/2024, Vol. 2024, p1-22. 22p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Change in the incidence of Parkinson's disease in a large UK primary care database.

Autor: Okunoye O; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK., Marston L; Department of Primary Care and Population Health, University College London, London, UK., Walters K; Department of Primary Care and Population Health, University College London, London, UK., Schrag A; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK. a.schrag@ucl.ac.uk.

Publikováno v: NPJ Parkinson's disease [NPJ Parkinsons Dis] 2022 Mar 15; Vol. 8 (1), pp. 23. Date of Electronic Publication: 2022 Mar 15.